BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7515694)

  • 1. Multiple myeloma.
    Seiden MV; Anderson KC
    Curr Opin Oncol; 1994 Jan; 6(1):41-9. PubMed ID: 7515694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of cytogenetics in multiple myeloma.
    Seong C; Delasalle K; Hayes K; Weber D; Dimopoulos M; Swantkowski J; Huh Y; Glassman A; Champlin R; Alexanian R
    Br J Haematol; 1998 Apr; 101(1):189-94. PubMed ID: 9576200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary disease in multiple myeloma.
    Bansal R; Rakshit S; Kumar S
    Blood Cancer J; 2021 Sep; 11(9):161. PubMed ID: 34588423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
    Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon therapy in multiple myeloma].
    Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):425-8. PubMed ID: 8273366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetics of extramedullary manifestations in multiple myeloma.
    Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
    Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma: biology of the disease.
    Mahindra A; Hideshima T; Anderson KC
    Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives.
    Haferlach T; Löffler H
    Leukemia; 1997 Dec; 11 Suppl 5():S5-9. PubMed ID: 9436931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
    Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
    Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma.
    Barlogie B; Alexanian R
    Cancer Res; 1989 Dec; 49(24 Pt 1):7172-5. PubMed ID: 2479477
    [No Abstract]   [Full Text] [Related]  

  • 12. Extramedullary multiple myeloma.
    Weinstock M; Ghobrial IM
    Leuk Lymphoma; 2013 Jun; 54(6):1135-41. PubMed ID: 23210572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of myeloma.
    Smith ML; Newland AC
    QJM; 1999 Jan; 92(1):11-4. PubMed ID: 10209667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of myeloma.
    Anderson KC; Carrasco RD
    Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology and therapy of multiple myeloma.
    Barlogie B; Alexanian R
    Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodeficiency and immunotherapy in multiple myeloma.
    Pratt G; Goodyear O; Moss P
    Br J Haematol; 2007 Sep; 138(5):563-79. PubMed ID: 17686051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of myeloma: recent developments.
    Zweegman S; Huijgens PC
    Anticancer Drugs; 2002 Apr; 13(4):339-51. PubMed ID: 11984079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.